Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Imugene Ltd

Healthcare AU IMU

0.092AUD
-0.001(1.08%)

Last update at 2026-06-05T06:11:00Z

Day Range

0.090.10
LowHigh

52 Week Range

0.090.54
LowHigh

Fundamentals

  • Previous Close 0.09
  • Market Cap39.50M
  • Volume2364991
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-46.91652M
  • Revenue TTM3.94M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM 3.94M
  • Diluted EPS TTM-0.23

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -69.02161M -154.29600M -39.17108M -37.86917M -18.45536M
Minority interest - - - - -
Net income -69.02161M -149.68100M -39.17108M -37.97592M -25.76667M
Selling general administrative 27.77M 59.91M 17.77M 12.10M 9.44M
Selling and marketing expenses - 11.70M 0.51M 0.33M 0.15M
Gross profit 4.40M 4.97M - - -
Reconciled depreciation 1.11M 3.29M 0.19M 0.20M 0.10M
Ebit -70.06411M -153.81800M -51.29082M -37.65758M -18.34433M
Ebitda -67.42317M -147.97800M -51.10050M -37.45422M -18.24013M
Depreciation and amortization 2.64M 5.84M 0.19M 0.20M 0.10M
Non operating income net other - - - - -
Operating income -70.94045M -140.93100M -51.29082M -37.65758M -18.34433M
Other operating expenses 75.34M 158.69M 51.29M 50.67M 25.67M
Interest expense 0.16M 0.48M - 0.11M 0.11M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 2.08M 4.52M 1.88M 0.19M 0.13M
Net interest income 1.92M 4.04M 1.85M 0.07M 0.01M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -4.04394M -4.61500M -1.84994M 0.11M 7.31M
Total revenue 4.40M 4.97M - 0.00000M 0.00000M
Total operating expenses 75.34M 135.09M 51.29M 50.67M 25.67M
Cost of revenue 3.38M 5.84M - - -
Total other income expense net 1.92M -13.36500M 10.27M -0.21159M -0.11103M
Discontinued operations - - - - -
Net income from continuing ops -69.02161M -149.68054M -39.17108M -37.86917M -18.45536M
Net income applicable to common shares -69.02161M -149.68054M -37.91489M -37.86917M -18.45536M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 83.59M 151.40M 195.81M 147.61M 71.81M
Intangible assets 31.69M 34.12M 30.49M 32.69M 34.89M
Earning assets - - - - -
Other current assets 5.50M 7.31M 0.40M 1.11M 0.17M
Total liab 38.56M 33.14M 7.44M 8.90M 6.79M
Total stockholder equity 45.03M 118.25M 188.37M 138.70M 65.02M
Deferred long term liab - - - - -
Other current liab 0.50M 22.42M 1.92M 1.42M 2.85M
Common stock - 370.31M 314.40M 230.79M 113.11M
Capital stock 380.68M 370.31M 314.40M 230.79M 113.11M
Retained earnings -352.72562M -289.83175M -142.69219M -103.52112M -65.65194M
Other liab - - 0.99M 0.99M 2.17M
Good will - - - - -
Other assets - - 0.02M 0.03M 0.02M
Cash 21.94M 93.11M 153.15M 99.89M 29.49M
Cash and equivalents - - 49.54M 29.00M 21.00M
Total current liabilities 22.15M 29.30M 6.08M 7.42M 4.46M
Current deferred revenue - - 1.63M 1.30M 0.74M
Net debt - -91.56061M -152.59719M -99.21429M -29.21600M
Short term debt - 0.91M 0.19M 0.18M 0.11M
Short long term debt 6.67M - - - -
Short long term debt total - 1.55M 0.55M 0.67M 0.27M
Other stockholder equity - - -172.96587M -127.26763M -47.45497M
Property plant equipment - - 0.68M 0.86M 0.47M
Total current assets 41.74M 113.03M 164.40M 113.77M 36.32M
Long term investments 0.22M 2.41M 0.22M 0.25M 0.12M
Net tangible assets - - 159.14M 106.02M 30.12M
Short term investments - 1.44M - -0.00000M -
Net receivables 8.73M 12.62M 10.85M 12.77M 6.66M
Long term debt 2.58M - - - -
Inventory - - - - -
Accounts payable 6.84M 5.97M 2.34M 4.51M 0.76M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 37.77M 16.66M 11.44M 17.56M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 8.20M 0.13M 0.02M 0.03M 0.02M
Deferred long term asset charges - - - - -
Non current assets total 41.84M 38.36M 31.41M 33.84M 35.49M
Capital lease obligations 1.40M - 0.55M 0.67M 0.27M
Long term debt total - - 0.36M 0.49M 0.17M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -12.69863M -7.25039M 1.89M -0.13717M -0.03456M
Change to liabilities - - -1.38542M 2.85M 0.03M
Total cashflows from investing activities -12.69863M -7.25039M 1.89M -0.22099M -5.32640M
Net borrowings 20.00M - -0.14741M -0.01081M 0.07M
Total cash from financing activities 17.37M 49.43M 82.98M 101.34M 17.99M
Change to operating activities - - 0.71M -0.94002M 0.02M
Net income -69.02161M -149.68054M -37.91489M -37.86917M -18.45536M
Change in cash -71.17211M -60.04312M 53.26M 70.40M -0.61973M
Begin period cash flow 93.11M 153.15M 99.89M 29.49M 30.11M
End period cash flow 21.94M 93.11M 153.15M 99.89M 29.49M
Total cash from operating activities -75.56852M -101.72614M -31.47096M -30.84814M -13.28001M
Issuance of capital stock 0.00158M 53.70M 88.17M 108.88M 18.05M
Depreciation - 5.84M 2.39M 2.41M 1.96M
Other cashflows from investing activities -5.14891M -0.17677M 1.89M 0.17M 0.16M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 5.41M -4.94342M 1.09M -6.10750M -2.45527M
Sale purchase of stock -1.32000M -2.73540M -5.04192M -6.15137M -0.12557M
Other cashflows from financing activities -1.31014M -1.53945M -0.14741M -1.38504M 0.06M
Change to netincome - - 3.64M 8.81M 5.62M
Capital expenditures 14.46M 7.07M 0.00000M 0.28M 5.45M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.80M 3.34M 1.09M -6.10750M -2.45527M
Stock based compensation - - 5.64M 4.10M 5.56M
Other non cash items -76.37312M 44.61M 4.05M 4.61M 3.21M
Free cash flow -90.02707M -108.79976M -31.47096M -31.12513M -18.72776M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IMU
Imugene Ltd		 -0.001 1.08% 0.09 - 13.30 10.01 1.05 4.85 -15.5112
CSL
CSL Ltd		 5.32 5.75% 97.91 10.77 13.61 2.87 1.71 2.71 8.15
TLX
TELIX Pharmaceuticals Ltd		 0.42 3.26% 13.31 - 2500.00 5.43 7.40 4.23 96.65
MSB
Mesoblast Ltd		 0.03 1.49% 2.05 - 454.55 39.94 3.31 30.21 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 0.12 0.89% 13.65 58.83 54.95 26.44 5.14 22.38 65.68

Reports Covered

Stock Research & News

View All

Profile

Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.

Imugene Ltd

4-6 Bligh Street, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD Exec. Chairman 1956
Ms. Leslie Chong CEO, MD & Exec. Director NA
Dr. Nicholas J. Ede B.Sc.(Hons.), Ph.D. Chief Technology Officer NA
Dr. Monil Shah M.B.A., Pharm.D. Chief Bus. Officer NA
Mr. Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD Chief Financial Officer 1966
Ms. Ursula McCurry Sr. VP of Clinical Operations NA
Dr. Giovanni Selvaggi Chief Medical Officer NA
Mr. Nathan Jong C.A. Joint Company Sec. NA
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD Executive Chairman 1956
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD Executive Chairman 1956

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.